Related Experiment Video

Updated: Aug 7, 2026

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells
10:24

Identification of Potential Anti-TB Candidates: A Step-by-Step Guide to Synthesis, MIC Determination, and Cytotoxicity Assessment in Mammalian Cells

Published on: May 22, 2026

Clinical development of anti-tuberculosis drugs

D A Mitchison1

  • 1St George's, University of London, Division of Cellular & Molecular Medicine Cranmer Terrace, London, UK. dmitchis@sgul.ac.uk

The Journal of Antimicrobial Chemotherapy
|July 15, 2006
PubMed

Insights

Optimizing Phase II tuberculosis drug trials is crucial. This study evaluates sputum sampling schedules to improve the efficiency of non-linear mixed effects modeling for assessing drug efficacy and treatment shortening potential.

Area of Science:

  • Pharmacometrics
  • Clinical Trial Design
  • Infectious Disease Research

Background:

  • Efficient Phase II studies are vital for anti-tuberculosis drug development.
  • Assessing treatment shortening and sterilizing activity requires robust clinical trial designs.
  • Non-linear mixed effects modeling of sputum colony-forming units (cfu) is a promising technique.

Purpose of the Study:

  • To investigate the relative efficiencies of different sputum sampling timing patterns in Phase II clinical trials for tuberculosis.
  • To inform the optimal design of novel clinical studies for anti-tuberculosis drug development.

Main Methods:

  • Analysis of serial sputum colony-forming unit (cfu) counts.
  • Application of non-linear mixed effects modeling.
  • Evaluation of various sputum sampling schedules and their impact on study efficiency.

Main Results:

  • The study reports on the relative efficiencies of different sputum sampling timing patterns.
  • Findings provide insights into optimizing the design of Phase II tuberculosis drug trials.

Conclusions:

  • Optimal sputum sampling schedules are essential for efficient Phase II tuberculosis drug development.
  • Improved study designs can enhance the assessment of drug efficacy and sterilizing activity.

More Related Videos

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis09:34

An Automated Culture System for Use in Preclinical Testing of Host-Directed Therapies for Tuberculosis

Published on: August 16, 2021

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis10:29

A High-throughput Compatible Assay to Evaluate Drug Efficacy against Macrophage Passaged Mycobacterium tuberculosis

Published on: March 24, 2017

Related Concept Videos

Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
Pulmonary Tuberculosis IV01:26

Pulmonary Tuberculosis IV

Tuberculosis, more commonly referred to as TB, is an infectious disease stemming from Mycobacterium tuberculosis. While it primarily impacts the lungs, TB can also affect other body areas. Given its severity and global impact, timely and accurate diagnosis is crucial for controlling its spread and improving patient outcomes.
Several diagnostic approaches are used to detect TB. The conventional method is the Tuberculin Skin Test (TST), also known as the Mantoux test. However, this method has...
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
Pulmonary Tuberculosis III01:31

Pulmonary Tuberculosis III

Tuberculosis (TB) is a contagious infection primarily affecting the lung parenchyma but which can also affect other body parts. TB can be classified based on disease development, presentation, and the affected anatomical site.
The first classification is based on the development of the disease, and it includes the following categories:
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Tuberculosis01:23

Tuberculosis

Tuberculosis (TB) remains a significant global health concern, primarily targeting the lungs and spreading through airborne transmission. Infection begins when aerosolized droplet nuclei, expelled by an individual with active TB, are inhaled by another person. These microscopic particles carry Mycobacterium tuberculosis, the causative agent of TB. Upon reaching the alveoli, the bacilli are engulfed by alveolar macrophages. However, due to their specialized lipid-rich cell wall, these pathogens...